Midatech Pharma Plc Current ratio
What is the Current ratio of Midatech Pharma Plc?
The Current ratio of Midatech Pharma Plc is 3.18
What is the definition of Current ratio?
Current ratio is a liquidity ratio that measures whether or not a company has enough resources to meet its short-term obligations.
mrq (most recent quarter)
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio of companies in the Health Care sector on LSE compared to Midatech Pharma Plc
What does Midatech Pharma Plc do?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Companies with current ratio similar to Midatech Pharma Plc
- EO2 has Current ratio of 3.18
- The Grob Tea has Current ratio of 3.18
- Avalara Inc has Current ratio of 3.18
- TORM plc has Current ratio of 3.18
- Buru has Current ratio of 3.18
- Brampton Brick has Current ratio of 3.18
- Midatech Pharma Plc has Current ratio of 3.18
- GHCL has Current ratio of 3.18
- co.don AG has Current ratio of 3.19
- Concurrent Technologies Plc has Current ratio of 3.19
- Forest Road Acquisition has Current ratio of 3.19
- Acheter-Louer.Fr SA has Current ratio of 3.19
- Credit Suisse AG has Current ratio of 3.19